Acadia Healthcare (ACHC) Q1 2026 earnings review
Operations Stabilize, But Earnings Quality Remains Poor
Under returning CEO Debbie Osteen, Acadia posted a 'back-to-basics' quarter that successfully arrested the operational freefall seen in late 2025. Revenue is accelerating, growing 7.6% YoY to $828.8M, driven by a strong rebound in the Acute Care segment. Adjusted EBITDA of $144.2M comfortably beat the company's internal expectations, prompting a slight raise in full-year guidance. However, the quality of these earnings is highly questionable. While non-GAAP metrics celebrate a recovery, GAAP Net Income collapsed 56% YoY to just $4.1M ($0.05 per share), weighed down by chronic 'adjustments' including $12.4M for ongoing government investigations and $13.7M in legal settlements. Operations are healing, but the balance sheet is still bleeding.
🐂 Bull Case
Acute inpatient volumes increased 6.2%, and revenue jumped 14% YoY. The aggressive capacity expansion of 2024-2025 is finally beginning to yield operational leverage.
Management raised FY26 Adjusted EBITDA guidance to $580-$615M (from $575-$610M) and Operating Cash Flow to $285-$325M, signaling confidence that the worst operational hiccups are behind them.
🐻 Bear Case
Government investigation costs ($12.4M), legal settlements ($13.7M), and a $10.3M reserve hike for Professional and General Liability (PLGL) completely erased operating gains at the net income level.
Specialty revenue dropped 6.5% YoY, driven by the lingering impact of New York's out-of-state Medicaid policy changes and subsequent facility closures in Pennsylvania.
⚖️ Verdict: ⚪
Neutral. The volume recovery and guidance raise prove core demand is intact and management is executing better. But until the chronic legal and liability costs step down materially, free cash flow generation will remain restricted.
Key Themes
Acute Inpatient Segment Accelerating
The Acute segment was the undeniable growth engine this quarter, with revenue accelerating to 14% YoY growth ($471M). Same-facility admissions jumped 6.5%, proving that the underlying demand for high-acuity behavioral health remains robust. The 82 new beds added in Q1 (42 to existing, 40 to new) are ramping up, providing the operational leverage that was missing in late 2025.
Specialty Segment Reversing Due to Macro Policy
Specialty treatment revenue fell 6.5% YoY to $128M. This segment has been decelerating for several quarters and is now actively shrinking. Management confirmed this relates to weakness in Pennsylvania facilities and the closures forced by the New York Medicaid policy change (which stopped out-of-state Medicaid coverage). This regulatory risk is actively destroying value in this specific segment.
Chronic 'One-Time' Legal Costs Masking True Profitability
Acadia's positive Adjusted EBITDA narrative is contradicted by its GAAP reality. The company reported $144M in Adj. EBITDA, but GAAP Net Income was just $4M. The difference? $22M in 'Transaction, legal and other costs' (including $12.4M for government investigations) and $13.7M in legal settlements. Management treats these as add-backs, but for investors, cash out the door is a very real drag on returns.
Strategic Pivot to Free Cash Flow
The era of unchecked capacity expansion is over. CapEx is firmly capped at $255-$280M for FY26 (down drastically from $572M in FY25). This forced capital discipline is a major driver for Acadia to transition from cash-burning growth to positive free cash flow generation, enabling them to comfortably service their 3.9x net leverage.
Quality Dashboards as a Commercial Tool
Acadia continues to lean into technology to defend against payer scrutiny and negative media. They are heavily utilizing remote patient monitoring, wearable safety devices for staff, and an integrated quality dashboard with over 50 real-time KPIs. This isn't just risk management; it is a primary driver for negotiating better rates with managed Medicaid and proving outcomes to referral sources.
Start-Up Losses Remain Elevated
The rapid addition of new facilities in late 2024 and 2025 is still creating a significant drag. Q2 2026 guidance assumes approximately $15M in start-up losses. While expected, this indicates that the 'embedded value' of the new beds will take time to materialize, suppressing margins in the near term.
Other KPIs
Accelerating. Up 5.6% YoY. This is a crucial metric, as it proves Acadia is successfully securing rate increases and a favorable payer mix (commercial/Medicare) to outpace inflation, despite the ongoing friction and utilization reviews from Managed Medicaid plans.
Stable. The leverage ratio remains manageable, calculated in accordance with their Credit Agreement. Due to out-of-period supplemental payment comps, management expects this to briefly spike to 4.4x-4.5x in Q2 before settling back to 3.9x-4.2x by year-end 2026.
Stable. Grew 4.9% YoY, which is slower than revenue growth (7.6%). On a per-patient-day basis, it increased only 3.3%. This indicates labor markets have cooled, premium pay is under control, and the company is capturing operating leverage on its largest expense line.
Guidance
Stable. Flat to slightly up sequentially from Q1's $144.2M. Management explicitly notes that Q2 guidance assumes no incremental new supplemental payments and includes $15M in drag from start-up losses for newly opened facilities.
Accelerating. The guidance was raised from the February estimate of $575-$610 million. However, when comparing to FY25's actual Adjusted EBITDA of $608.9 million, the midpoint of the new guidance ($597.5M) implies a slight YoY deceleration, largely driven by the loss of one-time state supplemental payments booked in the prior year.
Accelerating vs prior guidance. Raised from the February view of $1.30 - $1.55. However, this is still significantly below the FY25 Adjusted EPS of $2.00. The YoY decline reflects higher interest expenses, elevated depreciation from 2025 bed additions, and the lapping of 2025's massive Tennessee supplemental payment.
Accelerating. The forecast was raised by $5 million at both ends. Combined with firm CapEx guidance of $255-$280 million, this officially projects Acadia to generate positive Free Cash Flow in 2026, marking a major milestone in their strategic pivot.
Key Questions
Timeline for Legal Resolution
Government investigation costs ran at $12.4M this quarter. Is there a timeline or defined milestone for when these inquiries will conclude, or should investors underwrite this as a structural long-term expense?
Specialty Segment Strategy
With the Specialty segment reversing 7% YoY largely due to Pennsylvania and New York macro issues, are there plans to divest these specific underperforming assets rather than attempting to out-manage a structural policy disadvantage?
PLGL Reserve Trend
You recorded an incremental $10.3M reserve for Professional and General Liability this quarter, in line with expectations but still a significant drag. What leading indicators from your internal safety dashboards give you confidence these claims will eventually crest?